ABEO

Business Context and Reporting Period

Company: Abeona Therapeutics Inc. (ABEO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Abeona is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases. Its lead program is pz-cel, an autologous gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company also maintains a pipeline of AAV-based gene therapies for ophthalmic diseases (ABO-503, ABO-504, ABO-505) and holds strategic licensing agreements with partners such as Ultragenyx and Taysha Gene Therapies.

Key Financial Metrics

Note: The company reported no revenue in 2024 as no clinical development milestones were met. The 2023 revenue of $3.5 million was derived from a sublicense agreement with Taysha Gene Therapies.

Material Changes vs. Prior Period

• Revenue Decline: Revenue dropped 100% to $0 in 2024 compared to $3.5 million in 2023 due to the absence of achieved milestones.
• Increased Operating Expenses: Total expenses rose 27% to $64.2 million.
  • R&D: Increased 11% ($3.3 million) primarily due to higher salaries and stock-based compensation related to manufacturing capacity expansion for pz-cel.
  • G&A: Increased 57% ($10.9 million) driven by pre-commercial preparation costs, increased salaries, and professional fees.
• Debt Financing: The company entered a Loan and Security Agreement in January 2024, resulting in $20.0 million in principal debt and $4.2 million in interest expense for the year (compared to $0.4 million in 2023).
• Derivative Liabilities: The loss on the change in fair value of warrant and derivative liabilities decreased significantly to $0.8 million in 2024 from $11.7 million in 2023.

Guidance, Outlook, and Risks

Regulatory Status (pz-cel)

In April 2024, the FDA issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for pz-cel, citing Chemistry, Manufacturing, and Controls (CMC) requirements. The company resubmitted the BLA in October 2024. The FDA accepted the resubmission in November 2024 with a PDUFA target action date of April 29, 2025. The CRL did not identify deficiencies in clinical efficacy or safety data.

Liquidity and Capital Resources

As of December 31, 2024, the company held $98.1 million in cash resources. Management believes this is sufficient to fund operations for at least the next 12 months. The company continues to utilize its At-The-Market (ATM) equity offering agreement and recently secured a credit facility.

Key Risks

• Regulatory Approval: Failure to obtain FDA approval for pz-cel by the PDUFA date or at all would prevent commercialization.
• Manufacturing: As an autologous product, pz-cel faces complex manufacturing challenges; the company is expanding its Cleveland facility to increase capacity.
• Capital Requirements: The company has a history of losses and an accumulated deficit of $813.3 million. Future funding may be required, potentially leading to dilution.
• Competition: Competitors have received FDA approval for similar indications (Vyjuvek and Filsuvez), creating a competitive landscape.

Investor Verification Checklist

• BLA Resubmission Status: Verify the FDA's review progress on the pz-cel BLA resubmitted in October 2024 and the likelihood of meeting the April 29, 2025 PDUFA date.
• Manufacturing Capacity: Confirm the timeline for converting the new Euclid Avenue office space into manufacturing capacity to support commercial launch.
• Cash Burn Rate: Monitor quarterly cash burn and the sufficiency of the $98.1 million cash balance relative to the 12-month runway projection.
• Debt Covenants: Review the terms of the Avenue Venture Opportunities Fund loan, specifically the requirement to maintain $5 million in unrestricted cash and the interest rate (13.50% + Prime).
• Warrant Liability Volatility: Assess the impact of stock price fluctuations on the $32.0 million warrant liability, which is revalued quarterly.